1. Pink Sheet
  2. >>Compliance
  3. >>Marketing & Advertising

In Brief

Valeant picks up skin care OTCs from J&J; FDA finds ‘supplements’ making anti-meningitis claims; Capsugel supplies Mercola.com; investigation charge slows Omega Protein; Vitacost continues diversifying sales mix more news in brief.

Johnson & Johnson divests six OTC skin care brands to Valeant Pharmaceuticals International Inc. as part of its “ongoing portfolio management process,” according to a statement. In the deal completed in October, Montreal-based Valeant gained Ambi lotions and cleansers, Caladryl and Cortaid anti-itch products, Corn Huskers hand treatment lotion, Purpose sensitive skin care products and Shower to Shower body powder, all in North America, Latin America and most Asia-Pacific markets. During Valeant’s third-quarter earnings call Nov. 2, CEO J. Michael Pearson said the acquired products “are well-recognized brands and should continue to deliver strong cash flows.” Valeant seeks to build on its OTC dermatology business, which includes CeraVe cleansers and moisturizers and the AcneFree line ([A#05120702002]).

FDA finds products online making anti-meningitis claims, following meningitis infections linked to fungal contamination of an Rx compound produced and...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Marketing & Advertising

‘Sex Pill For Women’: Sprout CEO’s Addyi Instagram Post Draws US FDA Warning Letter

 
• By Sue Sutter

Cindy Eckert’s social media post with a People.com story failed to include any risk information, made misleading representations about benefits and omitted material information about the indication, said the agency, which flagged similar concerns about an Addyi radio ad five years ago.

Novo, Lilly Ad Challenges Cause Discontinued Claims For Compounded GLP-1s

 
• By Sue Sutter

Two pharmacies, a medical spa and a telehealth company voluntarily removed efficacy, safety and quality claims for compounded GLP-1 products after innovator companies filed challenges with the National Advertising Division.

Pharma DTC Ad Tax Break Targeted By US HHS, Congress

 
• By Derrick Gingery

Health and Human Services Secretary Robert F. Kennedy Jr. said a policy that would remove the tax write-off for pharma advertising expenses would be coming in a few weeks.

Sarfez Pharma’s Promotional Claims For Diuretic Soaanz Draw US FDA Warning Letter

 
• By Sue Sutter

Webpages, a healthcare professional pamphlet and a medical conference exhibit booth panel make unsupported comparative superiority claims about generic torsemide products and misrepresent risks, the Office of Prescription Drug Promotion says in its first warning letter of 2025.

More from Compliance

UK MHRA: Bacteriophage Developers Wanted ‘More Clarity’ On UK Framework

 
• By Eliza Slawther

Julian Beach, interim executive director of healthcare quality and access at the UK drug regulator, the MHRA, tells the Pink Sheet how the agency is responding to increased efforts to develop bacteriophage therapies.

Novo, Lilly Ad Challenges Cause Discontinued Claims For Compounded GLP-1s

 
• By Sue Sutter

Two pharmacies, a medical spa and a telehealth company voluntarily removed efficacy, safety and quality claims for compounded GLP-1 products after innovator companies filed challenges with the National Advertising Division.

EU Emergency Response Authority Needs Bigger Budget To Address Health Threats, Says Industry

 
• By Eliza Slawther

The EU must renew the mandate of its Health Emergency Response Authority to support medicine stockpiles and enable agile manufacturing to combat antimicrobial resistance and chemical, biological, radiological and nuclear threats, says trade organization EUCOPE.